Streamline: Retrospective Cohort Study of FMS-Like Tyrosine Kinase 3-Mutated Acute Myeloid Leukemia - Real-World Treatment Patterns and Clinical Outcomes of Patients in First Relapse or Refractory Diagnosis.

doi:10.1159/000545384

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Streamline: Retrospective Cohort Study of FMS-Like Tyrosine Kinase 3-Mutated Acute Myeloid Leukemia - Real-World Treatment Patterns and Clinical Outcomes of Patients in First Relapse or Refractory Diagnosis.

Acta haematologica - 1 Jan 2026

Zeidan Amer M, Yu Rebekah, Wang Yuexi, Lan Ziyu, Grinblatt David L, Elsouda Dina, Spalding James, Block Alana, Touya Maelys, Walker Mark S, Pandya Bhavik J

Abstract excerpt

<p>Introduction: Recent advances in genomic research have expanded the treatment landscape for acute myeloid leukemia (AML). This study examined treatment patterns and clinical outcomes among relapsed/refractory (R/R) FMS-like tyrosine kinase 3 (FLT3)-mutated AML patients. METHODS: This retrospective longitudinal study included patients with confirmed AML diagnosis, FLT3 mutation, and 1st R/R event from 1/1/2015...

Topics

Humans
fms-Like Tyrosine Kinase 3
Leukemia, Myeloid, Acute
Retrospective Studies
Female
Male
Middle Aged
Mutation
Aged
Adult

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Protein Kinase Inhibitors

Treatment Outcome

Recurrence

Aged, 80 and over

Young Adult

Drug Resistance, Neoplasm

Source

Open in PubMed Open full text

Identifiers

PMID: 40228486
DOI: 10.1159/000545384
PMCID: PMC12112888

Genes

FLT3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 29 Aug 2026. Prepared record publication-40228486-2026-08-29.1. Manifest publication-graph-cohort-2026-08-29.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 29 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Streamline: Retrospective Cohort Study of FMS-Like Tyrosine Kinase 3-Mutated Acute Myeloid Leukemia - Real-World Treatment Patterns and Clinical Outcomes of Patients in First Relapse or Refractory Diagnosis.PMID 40228486Read ↗

FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm.Semantic proximity Read ↗

FLT3 inhibitors and hematopoietic cell transplantation prolong survival in patients with FLT3-ITD-positive AMLSemantic proximity Read ↗

A real-world, retrospective, observational study examining treatment patterns and clinical outcomes in patients with FLT3m + AML in Japan.Semantic proximity Read ↗

A systematic review of second-generation FLT3 inhibitors for treatment of patients with relapsed/refractory acute myeloid leukemia.Semantic proximity Read ↗

[Breakthroughs in FLT3-mutated acute myeloid leukemia treatments].Semantic proximity Read ↗

Characteristics and Outcome of FLT3-ITD-Positive Acute Myeloid Leukemia.Semantic proximity Read ↗

Real-World Outcomes of Acute Myeloid Leukemia Patients Undergoing Treatment With Tyrosine Kinase Inhibitor (TKI) Therapy Targeting FLT3, IDH1, or IDH2.Semantic proximity Read ↗

Effectiveness of Gilteritinib Beyond Second-Line Therapy in Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia: A Real-World Multicenter Study of 171 Patients.Semantic proximity Read ↗

Improved outcomes among newly diagnosed patients with FMS-like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification.Semantic proximity Read ↗

Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort.Semantic proximity Read ↗

Optimizing treatment selection and timing of allogeneic haematopoietic stem cell transplantation in acute myeloid leukaemia with concurrent feline McDonough sarcoma (FMS)-like tyrosine kinase 3 internal tandem duplication, nucleophosmin 1 and deoxyribonucleic acid (DNA) methyltransferase 3 alpha mutations.Semantic proximity Read ↗

Improved Posttransplant Outcomes in Recent Years for AML Patients with FLT3-ITD and Wild-type NPM1: A Report from the EBMT Acute Leukemia Working Party.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.